Hi, Folks,
I'm back from my Yosemite trip. Priceless experience at the cost of a few abrasions. Three classic grade IV (climbs that take an average party all day, usually more than 1,000 feet) routes. And yes, Stefaan, contrary to my own expectation I did climb the "Big Rock." To it's right shoulder, anyhow: East Buttress of El Capitan (5.9, IV, for those who understand the numbers). Rick, my hat is off to you & others for doing Half Dome. That seems like a long day. Lord knows, my quadriceps were getting thrashed from the steep approaches and descents; the climbs themselves were relatively easy on them. Lost a few pounds.
I'm not sure if this means anything dramatic for the companies involved, but the taking of the non-litiguous path is encouraging.
>>BILLERICA, Mass. & FOSTER CITY, Calif., Jun 7, 2001 (BW HealthWire) -- Bruker Daltonics Inc. (NASDAQ: BDAL chart, msgs), Applied Biosystems Group (NYSE: ABI chart, msgs), an Applera Corporation business, and Indiana University's Advanced Research & Technology Institute (IU-ARTI), the technology transfer arm of Indiana University, today announced an agreement for the licensing of a portfolio of significant mass spectrometry patents. As part of the agreement, Bruker Daltonics has been appointed the exclusive agent for licensing this combined intellectual property to the life-science industry. Financial terms of the agreement were not disclosed.
These patent portfolios relate to MALDI-TOF mass spectrometry and cover the significant technology called Space-Velocity Correlation Focusing (SVCF), or Delayed Extraction (DE). This technology improves both accuracy and sensitivity, and is implemented in most modern MALDI-TOF systems. As licensing agent for IU-ARTI's SVCF patents, Bruker Daltonics has granted Applied Biosystems a sub-license in exchange for multi-year royalty payments. Bruker Daltonics and Applied Biosystems also have cross-licensed each other on their respective patent portfolios related to this technology.
Frank H. Laukien, President and CEO of Bruker Daltonics, and Michael W. Hunkapiller, Ph.D., President of Applied Biosystems, said, "We expect that this agreement will further strengthen the important role that MALDI-TOF mass spectrometry plays today in genotyping and proteomics. We believe that it is in the best interest of our customers in this field to jointly promote the MALDI-TOF market via a licensing program."<<
snip
Cheers, Tuck |
